<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11959" href="/d/html/11959.html" rel="external">see "Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="132253" href="/d/html/132253.html" rel="external">see "Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F176566"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Endari;</li>
<li>Glutasolve</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F176578"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Amino Acid;</li>
<li>
                        Gastrointestinal Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F176567"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68fae5b1-95e7-495c-840c-067e2a478327">Oral mucositis prevention, in patients with head and neck cancer receiving chemoradiotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral </b>
<b>mucositis prevention, in patients with head and neck cancer receiving chemoradiotherapy (off-label use): Oral: </b>10 g 3 times daily throughout chemoradiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25351453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25351453'])">Ref</a></span>) <b>or</b> 10 to 30 g/day during chemoradiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32786044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32786044'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b6a9e50-ed98-4ee4-8a59-1ac97382a77d">Sickle cell disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sickle cell disease</b>
<b>:</b> Endari: <b>Note:</b> Only the Endari brand/formulation is approved for sickle cell disease (SCD); avoid the use of other glutamine formulations for SCD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29895661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29895661'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention of vaso-occlusive pain in patients with frequent episodes (≥2 in the prior year), either as an adjunct to hydroxyurea or as an alternative in patients unable to tolerate hydroxyurea</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9625578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9625578'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: <b>Oral:</b> 5 g (1 packet) twice daily (total dose 10 g/day).</p>
<p style="text-indent:-2em;margin-left:6em;">30 to 65 kg: <b>Oral: </b>10 g (2 packets) twice daily (total dose 20 g/day).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;65 kg: <b>Oral: </b>15 g (3 packets) twice daily (total dose 30 g/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc6ce444-ae31-459d-8651-697885a1c8fc">Supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supplement (nutritional):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Several products are available and specific dosing may not be represented here; refer to manufacturer labeling for product-specific dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">GlutImmune, GlutaMent, GlutaSolve, Glutapak-10, Sympt-X: <b>Oral: </b>Average dose: 10 g 3 times per day; dosing range: 5 to 30 g/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Glutamine (capsules, tablets): <b>Oral:</b> 500 mg daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990450"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987657"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F3062830"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F46273484"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="132253" href="/d/html/132253.html" rel="external">see "Glutamine (including L-glutamine [pharmaceutical grade] and supplements): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose is presented as grams of l-glutamine.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b6a9e50-ed98-4ee4-8a59-1ac97382a77d">Sickle cell disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sickle cell disease:</b>
<b>Note:</b> Only the Endari brand/formulation is approved for sickle cell disease (SCD); avoid the use of other glutamine formulations for SCD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29895661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29895661'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Endari: Oral Powder:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: Oral: 5 g (1 packet) twice daily; total daily dose: 10 g/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to 65 kg: Oral: 10 g (2 packets) twice daily; total daily dose: 20 g/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;65 kg: Oral: 15 g (3 packets) twice daily; total daily dose: 30 g/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc6ce444-ae31-459d-8651-697885a1c8fc">Supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supplement (nutritional):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Sympt-X: Children and Adolescents: Oral: 0.25 to 0.5 g/kg/day given in 3 divided doses; usual adult dose: 10 g/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Glutasolve: Children &gt;3 years and Adolescents: Oral: 15 g (1 packet)/dose; frequency determined based on patient's clinical status, indication, and nutritional assessment.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112243"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Nutritional supplements/medical foods are contraindicated in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51112244"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Nutritional supplements/medical foods are contraindicated in liver impairment.</p></div>
<div class="block adr drugH1Div" id="F176545"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17%), constipation (21%), nausea (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (12%), limb pain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hypersplenism</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Burning sensation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hepatic: Hepatotoxicity (Hatami 2020)</p></div>
<div class="block coi drugH1Div" id="F46273482"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Endari: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: Renal or liver impairment; Reye syndrome; shock; multi-organ failure</p></div>
<div class="block war drugH1Div" id="F176543"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment.</p></div>
<div class="block dosfc drugH1Div" id="F57241036"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Sympt-X is available in US in 300 g jars, 500 g jars and packets (10 g L-glutamine + 5 g maltodextrin)</p></div>
<div class="block foc drugH1Div" id="F176551"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Packet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Endari: 5 g (1 ea, 60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;">Glutasolve: 15 g (1 ea, 56 ea)</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F20452547"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323171"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Glutamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Endari Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $26.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F176553"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Endari: Mix each dose with 240 mL cold or room temperature beverage (eg, water, milk, apple juice) or with 120 to 180 mL of food (eg, applesauce or yogurt). Complete dissolution is not required prior to administration. Prepare immediately prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">GlutaMent: Do not mix with hot beverages as this may reduce potency; mix 1 packet with 120 to 180 mL of water, juice or other liquid. May also add to applesauce, pudding, or yogurt. For mucositis, mix each 10 g packet with 120 mL water; administer using a swish-and-swallow technique. If administering via feeding tube, mix 1 packet with 30 mL water; mix well and administer slowly via syringe; flush with 15 to 30 mL water before and after administration. Do not mix directly with enteral formula.</p>
<p style="text-indent:-2em;margin-left:4em;">Glutapak-10: Prior to use, mix with 60 to 120 mL liquid or semisolid food. If administering via feeding tube, mix each 10 g packet with 60 to 120 mL water, and flush feeding tube before and after administration. Do not mix directly with enteral formula. Use immediately after preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">GlutaSolve: Mix each 22.5 g packet (containing l-glutamine 15 g) with 120 mL water. May also be mixed in hot or cold beverages, applesauce, pudding, or yogurt. If administering via feeding tube, mix with 60 to 120 mL warm water for 20 seconds. Flush tube with 15 to 30 mL water before and after administration. Use immediately after preparation. Do not mix directly with enteral formula.</p>
<p style="text-indent:-2em;margin-left:4em;">GlutImmune: Mix with food or hot or cold beverages.</p>
<p style="text-indent:-2em;margin-left:4em;">Sympt-X: Mix dose (10 g) with 180 to 240 mL water, juice, or another beverage; may also be mixed with semi-solid foods such as yogurt or smoothie. Use immediately after preparation. May administer via feeding tube.</p></div>
<div class="block admp drugH1Div" id="F52612926"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Endari: Children ≥5 years and Adolescents: Mix each dose with 240 mL cold or room temperature beverage (eg, water, milk, apple juice) or with 4 to 6 ounces of semi-solid food (eg, applesauce, yogurt); do not use hot beverage or food. Complete dissolution is not required prior to administration. Prepare immediately prior to administration; do not save for later use.</p>
<p style="text-indent:-2em;margin-left:2em;">Glutasolve: Children &gt;3 years and Adolescents: Mix each 22.5 g packet (containing l-glutamine 15 g) with 120 mL hot or cold beverage. May also be mixed in applesauce, pudding, or yogurt. Stir well and use immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Feeding tube administration:</i> Mix with 60 to 120 mL warm water; do not mix directly with enteral formula. Flush tube with 15 to 30 mL water before and after administration. Use immediately after preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">Sympt-X: Children and Adolescents: Mix dose with 180 to 240 mL water, juice, or another beverage (&lt;40°C [104°F]); may not completely dissolve; may also be mixed with semi-solid foods such as yogurt or smoothie. Use immediately after preparation. May administer via feeding tube.</p></div>
<div class="block use drugH1Div" id="F176552"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sickle cell disease (Endari only):</b> To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older.</p>
<p style="text-indent:-2em;margin-left:4em;">In the clinical trial, Endari was used for the prevention of vaso-occlusive pain in patients with frequent episodes (≥2 in the prior year), either as an adjunct to hydroxyurea or as an alternative in patients unable to tolerate hydroxyurea (Niihara 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Supplement (nutritional):</b> Medical food used to promote GI tract healing and nutritional supplementation with GI disorders, HIV/AIDS, cancer, and other critical illnesses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A medical food is formulated to be administered enterally under the supervision of a physician and is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements are established by medical evaluation. Medical foods are not drugs and, therefore, are not subject to any FDA regulatory requirements that specifically apply to drugs (eg, requirement for written/oral prescription prior to dispensing, premarket review or approval, proof of safety and efficacy).</p></div>
<div class="block off-label drugH1Div" id="F56136718"><span class="drugH1">Use: Off-Label: Adult</span><p>Oral mucositis prevention, in patients with head and neck cancer receiving chemoradiation</p></div>
<div class="block cyt drugH1Div" id="F30151844"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F30151841"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Lactulose: Glutamine may diminish the therapeutic effect of Lactulose. Specifically, glutamine may diminish the ammonia-lowering effects of lactulose. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Glutamine may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F176556"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Endogenous glutamine can be detected in cord blood and concentrations are decreased in low birth-weight infants (Ivorra 2012).</p></div>
<div class="block brc drugH1Div" id="F176557"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Endogenous glutamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F176549"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function, hepatic function</p></div>
<div class="block pha drugH1Div" id="F176542"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Glutamine is considered a "conditionally essential" amino acid during metabolic stress and injury. Glutamine is a precursor for nicotinamide adenine dinucleotide (NAD). In sickle cell disease, NAD and its reduced form, NADH, have a role in regulating and preventing red blood cell oxidative damage; in sickle red blood cells, the ratio of NADH to total NAD is lower, which results in a decreased NAD redox potential (Niihara 1998). Glutamine may improve NAD redox potential in sickle red blood cells through increased availability of reduced glutathione.</p></div>
<div class="block phk drugH1Div" id="F176555"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Adults (healthy): IV: V<sub>d</sub>: ~200 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic metabolism to glutamate and ammonia</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults (healthy): IV: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Adults (healthy): ~30 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50888908"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Glutamina 5800 Max | Impi d | L Glutamina | L glutamina hw | Levoglutamina Ch | Vitalil k glutam pure</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Healthwise l glutamine | L-Glutamine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Glutaflora | Glutamin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An kai shu | Ci mo | Glutamine | Xin mai lin | Zi wei</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adamin g | Glutabrain | Glutamin | L glutamin | L-Glutamine | Naturafit glutamin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">L glutamine | Now l glutamine</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Axion | Glutrop</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Lgm</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glutacerebro | Glutammina | Glutammina named | Glutaven | Pro muscle glutamine recovery</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Glumin | Glutamid | Glutamine | Hokkalugen | L glutamine nipro</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">L-Glutamine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">L glutamine | L-Glutaminas</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">L-Glutamine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">L glutamin synopharm | L glutamine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adamin g | Glutamine | Radiance amino glutamine | Solgar l glutamine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adamin g</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Endari</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gnc pro performance l glutamine | L glutamine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Glutamine 800</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Levoglutamine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">L-Glutamine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Watanabe glutamine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Glutamina | L-Glutamine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Glutamine | Glutazorb | L glutamine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32786044">
<a name="32786044"></a>Elad S, Cheng KKF, Lalla RV, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2020;126(19):4423-4431. doi:10.1002/cncr.33100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/32786044/pubmed" id="32786044" target="_blank">32786044</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Endari (glutamine) [prescribing information]. Torrance, CA: Emmaus Medical, Inc; October 2020.</div>
</li>
<li>
<div class="reference">
                  GlutaMent (glutamine) [prescribing information]. Lancaster, PA: Medtrition, Inc; received June 2021.</div>
</li>
<li>
<div class="reference">
                  Glutamine capsules [prescribing information]. Fayetteville, AR: BioTech Pharmacal; received August 2015.</div>
</li>
<li>
<div class="reference">
                  Glutapak-10 (glutamine) [prescribing information]. Miami, FL: Victus; received January 2016.</div>
</li>
<li>
<div class="reference">
                  Glutasolve (glutamine) [prescribing information]. Florham Park, NJ: Nestle Health Science; received May 2019.</div>
</li>
<li>
<div class="reference">
                  GlutImmune (glutamine) [prescribing information]. San Diego, CA: Wellwisdom, LLC; received November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32190229">
<a name="32190229"></a>Hatami B, Saffaei A, Jamali F, Abbasinazari M. Glutamine powder-induced hepatotoxicity: it is time to understand the side effects of sports nutritional supplements. <i>Gastroenterol Hepatol Bed Bench</i>. 2020;13(1):86-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/32190229/pubmed" id="32190229" target="_blank">32190229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>. Washington, DC: National Academies Press; 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776444">
<a name="22776444"></a>Ivorra C, García-Vicent C, Chaves FJ, Monleón D, Morales JM, Lurbe E. Metabolomic profiling in blood from umbilical cords of low birth weight newborns. <i>J Transl Med</i>. 2012;10:142. doi: 10.1186/1479-5876-10-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/22776444/pubmed" id="22776444" target="_blank">22776444</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  L-Glutamine tablets [prescribing information]. Long Island City, NY: Freeda Vitamins; received August 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398613">
<a name="19398613"></a>Martindale RG, McClave SA, Vanek VW, et al, “Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.),” <i>JPEN J Parenter Enteral Nutr</i>, 2007, 33(3):277-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/19398613/pubmed" id="19398613" target="_blank">19398613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30021096">
<a name="30021096"></a>Niihara Y, Miller ST, Kanter J, et al; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A phase 3 trial of l-glutamine in sickle cell disease. <i>N Engl J Med</i>. 2018;379(3):226-235. doi: 10.1056/NEJMoa1715971.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/30021096/pubmed" id="30021096" target="_blank">30021096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9625578">
<a name="9625578"></a>Niihara Y, Zerez CR, Akiyama DS, et al. Oral l-glutamine therapy for sickle cell anemia: subjective clinical improvement and favorable change in red cell NAD redox potential. <i>Am J Hematol.</i> 1998;58(2):117-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/9625578/pubmed" id="9625578" target="_blank">9625578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29895661">
<a name="29895661"></a>Quinn CT. l-glutamine for sickle cell anemia: more questions than answers. <i>Blood</i>. 2018;132(7):689-693. doi: 10.1182/blood-2018-03-834440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/29895661/pubmed" id="29895661" target="_blank">29895661</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sympt-X (glutamine) [prescribing information]. Richardson, Texas; TSPC America, Inc: September 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25351453">
<a name="25351453"></a>Tsujimoto T, Yamamoto Y, Wasa M, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. <i>Oncol Rep</i>. 2015;33(1):33-39. doi:10.3892/or.2014.3564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glutamine-including-l-glutamine-pharmaceutical-grade-and-supplements-drug-information/abstract-text/25351453/pubmed" id="25351453" target="_blank">25351453</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8747 Version 139.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
